AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 81 min read$HAE

Haemonetics gains after update on CSL supply deal (HAE:NYSE)

Haemonetics (HAE) rose ~14% premarket Thursday after CSL Limited (CSLLY) announced plans to use HAE's devices in its U.S. plasma centers, per a prior supply agreement.

Original reporting
seekingalpha.com
Published Oct 8, 2026, 11:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$HAE
Bullish
high confidence
Mentioned
$HAE
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$HAEBullishHigh
01

Why it matters

The announcement triggered a 14% pre‑market surge, indicating strong market confidence in the partnership.

02

Market read

The deal provides a clear growth catalyst for Haemonetics, likely supporting short‑term upside.

03

What to watch

Potential regulatory approvals for the devices in the U.S. could affect execution.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Haemonetics announced a supply agreement with CSL Limited, a leading biopharma company, to place its plasma collection devices in CSL's U.S. centers.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Haemonetics shares jumped ~14% pre‑market after CSL Limited confirmed deployment of its devices in U.S. plasma collection centers.

Expected impact

upward pressure as the market prices in the new CSL deployment.

Evidence & confidence

A material supply agreement with a major partner and a double‑digit pre‑market move indicate fresh, actionable catalyst.

Market effects

Sector

Positive signal for medical device and plasma‑collection equipment sector.

Regional

U.S. biotech/medical device market may see modest uplift.

Global

Limited to companies with similar supply‑chain partnerships.

Counterpoint

What could challenge this read

If the deployment timeline slips, the rally could reverse.

Key entities

  • Company
    Haemonetics

    Medical device maker (ticker HAE).

  • Company
    CSL Limited

    Biopharma firm (ticker CSLLY) partnering with Haemonetics.

Read at source← All news

Related articles

AUG 19
$HAEHighAI 8/10

Haemonetics reconnects with CSL in US plasma collection deal

Haemonetics (HAE) announced a new deal with CSL Plasma to supply its NexSys PCS platforms and apheresis kits for U.S. plasma collection centers. The contract, following FDA approval, does not have minimum purchase requirements. HAE shares rose 15% in after-hours trading, reaching $107. Analysts estimate potential revenue of $183M-$223M annually if CSL fully switches back, with a 6%-8% growth rate and 10%-20% pricing premium.

massdevice.com2 min
AUG 18
$HAEMedAI 8/10

Up another 16% TODAY, see why this AI-picked medtech stock is now up +92%

Haemonetics Corporation (NYSE:HAE) rose 15.9% after announcing a supply agreement with CSL Plasma, adding to its 91.88% surge since being identified by InvestingPro's AI models. The company reported Q1 2027 revenue of $339.4M and adjusted EPS of $1.14, raising its full-year revenue growth outlook to 5-8%. InvestingPro's AI-powered stock picker has identified multiple stocks with significant gains, including Haemonetics, which was highlighted for its valuation, profitability, and growth potential

investing.com7 min
AUG 18
$HAEMed

Haemonetics stock surges 16% on CSL Plasma supply deal

Haemonetics (NYSE:HAE) shares rose 16.3% after it announced a non-exclusive U.S. supply agreement with CSL Plasma. Signed Aug. 14, 2026, it allows CSL to use Haemonetics NexSys PCS devices with Persona PLUS and buy related disposables, with no minimum purchase commitments. Haemonetics did not revise fiscal 2027 guidance and plans an update at its Q2 earnings call in Nov. 2026.

investing.com4 min
AUG 18
$HAEHighAI 9/10

Why is Haemonetics stock surging today?

Haemonetics (HAE) shares rose about 6.6% in pre-open after the company filed an 8-K for a non-exclusive supply agreement with CSL Plasma. The deal lets CSL deploy Haemonetics NexSys PCS devices with Persona PLUS and buy related disposables at U.S. centers. Investors also cited Haemonetics’ Aug. 6 Q1 FY2027 results: $339.4M revenue, $1.14 adjusted EPS, and raised FY2027 growth guidance to 5%–8%, plus analyst target increases.

investing.com4 min